Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Businesswire
Mon, 08/29/22 - 10:26 am
Tags:
Alnylam Pharmaceuticals, clinical trials, cemdisiran, Regeneron, IgAN, immunoglobultin A nephropathy, RNAi
Drug makers leave the pain behind
EP Vantage
Fri, 08/26/22 - 10:26 am
Tags:
painkillers, Acadia, Eli Lilly, Ampio Pharmaceuticals, Aptinyx, Eliem Therapeutics, Vertanical, Teva Pharamceutical, Regeneron, Vivozon, Vertex Pharmaceuticals, Biogen
Kodiak matches Regeneron’s Eylea in macular edema phase 3, lighting Beacon of hope after flop
Fierce Biotech
Tue, 08/9/22 - 06:34 am
Tags:
Kodiak Sciences, Regeneron, Bayer, Eylea, macular edema, clinical trials, tarcocimab
Regeneron's Dupixent and Eylea Offset Drop in COVID-19 Antibody Sales
BioSpace
Wed, 08/3/22 - 09:19 pm
Tags:
Regeneron, earnings, COVID-19, Eylea, Dupixent
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Fierce Pharma
Mon, 07/25/22 - 10:00 pm
Tags:
Regeneron, Eylea, Roche, Vabysmo
Regeneron, Sanofi Look to Extend Dupixent into Young Kids with Eosinophilic Esophagitis
BioSpace
Thu, 07/14/22 - 11:49 am
Tags:
Regeneron, Sanofi, Dupixent, pediatric, eosinophilic esophagitis
Regeneron completes acquisition of Sanofi’s stake in Libtayo
Pharmaceutical Business Review
Mon, 07/4/22 - 11:58 pm
Tags:
Regeneron, Sanofi, Libtayo, cancer
Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA
Motley Fool
Mon, 06/27/22 - 10:12 am
Tags:
Sanofi, Regeneron, FDA, Dupixent, eosinophilic esophagitis
Regeneron Breaks Ground on $1.8B NY Expansion Project
BioSpace
Thu, 06/23/22 - 10:41 am
Tags:
Regeneron, New York
Regeneron's Eylea could lose 30% of its patients to Roche's Vabysmo over the next year: analyst survey
Fierce Pharma
Mon, 06/13/22 - 09:46 pm
Tags:
Regeneron, Eylea, Vabysmo, Roche, wet-AMD
FDA approves Sanofi and Regeneron’s Dupixent for atopic dermatitis in young children
Pharmaceutical Business Review
Wed, 06/8/22 - 10:44 am
Tags:
Sanofi, Regeneron, FDA, pediatric, atopic dermatitis, Dupixent
Regeneron purchases Sanofi’s stake in Libtayo collaboration
Biopharma Reporter
Thu, 06/2/22 - 10:27 am
Tags:
Regeneron, Sanofi, Libtayo
Regeneron's cholesterol drug war heats up with lawsuit over Amgen's 'illegal' bundling scheme
Fierce Pharma
Wed, 06/1/22 - 07:36 pm
Tags:
Regeneron, Amgen, FDA, antitrust, legal, Repatha, Praluent
FDA grants speedy review to Dupixent rare skin disease
Pharmaforum
Tue, 05/31/22 - 10:43 am
Tags:
Sanofi, Regeneron, Dupixent, prurigo nodularis, FDA
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
Motley Fool
Thu, 05/26/22 - 10:08 am
Tags:
Regeneron, patents, patent cliff, Eylea
Sanofi's Dupixent scores big as the first FDA-approved treatment for eosinophilic esophagitis
Fierce Pharma
Sun, 05/22/22 - 09:15 pm
Tags:
Sanofi, Regeneron, Dupixent, FDA, eosinophilic esophagitis
Is Regeneron In Trouble After Sales Declined 40% In a Single Quarter?
Motley Fool
Thu, 05/12/22 - 10:15 am
Tags:
Regeneron, earnings
The 12 Top Biotech Companies Hiring Now
BioSpace
Tue, 05/10/22 - 10:26 pm
Tags:
biotech, life sciences, hirings, Regeneron, Pfizer, Amgen, AbbVie, Moderna Therapeutics, CSL Behring, Waters Corporation, Daiichi Sankyo, Gilead Sciences, Grail, Emergent BioSolutions, resilience
Regeneron tries to shake off fall in COVID drug sales with first quarter earnings
BioPharma Dive
Wed, 05/4/22 - 05:44 pm
Tags:
Regeneron, earnings
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
Yahoo/Zacks.com
Fri, 04/29/22 - 10:17 am
Tags:
COVID-19, earnings, Novo Nordisk, Biogen, Regeneron, Moderna Therapeutics, Vertex Pharmaceuticals

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.